Skip to main content
Best News Website or Mobile Service
WAN-IFRA Digital Media Awards Worldwide 2022
Best News Website or Mobile Service
Digital Media Awards Worldwide 2022
Hamburger Menu




US grants emergency approval to Eli Lilly COVID-19 antibodies

US grants emergency approval to Eli Lilly COVID-19 antibodies

The US Food and Drug Administration cleared emergency use of Bamlanivimab, the first antibody drug to help the immune system fight COVID-19 (Photo: Courtesy of Eli Lilly via AP)

WASHINGTON: The US Food and Drug Administration on Monday (Nov 10) granted emergency approval to a synthetic antibody treatment against COVID-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalisation and emergency room visits.

Bamlanivimab at a dose of 700 mg was authorised for the treatment of mild-to-moderate COVID-19 in adults and children aged 12 years and older who are at high risk for progressing to the severe form of the disease.

It is the first major drug to be approved that was designed specifically against the new coronavirus.

"As illustrated by today's action, the FDA remains committed to expediting the development and availability of potential COVID-19 treatments," said the agency's chief Stephen Hahn.

READ: Eli Lilly COVID-19 antibody trial paused due to potential safety concern

READ: US strikes deal with AstraZeneca for COVID-19 antibody treatment touted by Trump

The approval was based on a mid-stage clinical trial for outpatients with mild to moderate COVID-19, where the intravenous treatment was shown to reduce viral loads and rates of symptoms and hospitalidation.

The FDA said in its statement that the most important evidence that bamlanivimab may be effective came from data that showed that among patients at high risk of severe disease, hospitalizations and emergency room visits occurred in 3 per cent of bamlanivimab-treated patients compared to 10 per cent who were on the placebo.

The frequency and types of side effects were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity.

The most common were diarrhoea, dizziness, headache, itchiness and vomiting.

The trial is ongoing and aims to enroll more than 800 patients across various dosage groups.

An important caveat is that bamlanivimab has not been authorised for patients who are hospitalised - since no benefit has been shown for patients who are already in this late stage of the disease, when the body's immune defenses go into overdrive and damage organs.

READ: WHO-led COVID-19 drug scheme doubles down on antibodies, steroids and shuns remdesivir

READ: Eli Lilly in deal to supply COVID-19 drugs to low-income countries

The FDA wrote that administering the drug too late could be associated with worse outcomes, and a trial exploring bamlanivimab in hospitalised patients was suspended last month over a safety incident.

Bamlanivimab is what's known as a monoclonal antibody, a relatively new class of drugs that are best known for treating certain types of cancer and autoimmune disease.

Human immune systems produce antibodies, which are infection-fighting proteins, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens.

Bamlanivimab was based on an effective antibody Lilly found in a recovered patient.

The host immune cells that produce the antibodies can be cultured in a lab to produce the desired proteins en masse.

It works by binding to a surface protein of the coronavirus to stop it from invading human cells.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: AFP/lk


Also worth reading